Global Stomach Peptic Ulcer Treatment 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06251337

Publication Date:

June 27, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Stomach Peptic Ulcer Treatment market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淪tomach Peptic Ulcer Treatment Industry Forecast鈥� looks at past sales and reviews total world Stomach Peptic Ulcer Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Stomach Peptic Ulcer Treatment sales for 2025 through 2031. With Stomach Peptic Ulcer Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Stomach Peptic Ulcer Treatment industry.
This Insight Report provides a comprehensive analysis of the global Stomach Peptic Ulcer Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Stomach Peptic Ulcer Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Stomach Peptic Ulcer Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Stomach Peptic Ulcer Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Stomach Peptic Ulcer Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Stomach Peptic Ulcer Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Proton Pump Inhibitors
Potassium-Competitive Acid Blockers (P-CABs)
Antacids
Others
Segmentation by Application:
Hospital
Specific Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Daewoong Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Abbott Laboratories
AstraZeneca plc.
Cadila Healthcare Ltd.
Boehringer Ingelheim GmbH
Eisai Co. Ltd.
Yuhan Corporation
GlaxoSmithKline plc.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Stomach Peptic Ulcer Treatment 麻豆原创 Size (2020-2031)
2.1.2 Stomach Peptic Ulcer Treatment 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Stomach Peptic Ulcer Treatment by Country/Region (2020, 2024 & 2031)
2.2 Stomach Peptic Ulcer Treatment Segment by Type
2.2.1 Proton Pump Inhibitors
2.2.2 Potassium-Competitive Acid Blockers (P-CABs)
2.2.3 Antacids
2.2.4 Others
2.3 Stomach Peptic Ulcer Treatment 麻豆原创 Size by Type
2.3.1 Stomach Peptic Ulcer Treatment 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Stomach Peptic Ulcer Treatment 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Stomach Peptic Ulcer Treatment Segment by Application
2.4.1 Hospital
2.4.2 Specific Clinic
2.4.3 Others
2.5 Stomach Peptic Ulcer Treatment 麻豆原创 Size by Application
2.5.1 Stomach Peptic Ulcer Treatment 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Stomach Peptic Ulcer Treatment 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Stomach Peptic Ulcer Treatment 麻豆原创 Size by Player
3.1 Stomach Peptic Ulcer Treatment 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Stomach Peptic Ulcer Treatment Revenue by Player (2020-2025)
3.1.2 Global Stomach Peptic Ulcer Treatment Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Stomach Peptic Ulcer Treatment Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Stomach Peptic Ulcer Treatment by Region
4.1 Stomach Peptic Ulcer Treatment 麻豆原创 Size by Region (2020-2025)
4.2 Global Stomach Peptic Ulcer Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Stomach Peptic Ulcer Treatment 麻豆原创 Size Growth (2020-2025)
4.4 APAC Stomach Peptic Ulcer Treatment 麻豆原创 Size Growth (2020-2025)
4.5 Europe Stomach Peptic Ulcer Treatment 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Stomach Peptic Ulcer Treatment 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Stomach Peptic Ulcer Treatment 麻豆原创 Size by Country (2020-2025)
5.2 Americas Stomach Peptic Ulcer Treatment 麻豆原创 Size by Type (2020-2025)
5.3 Americas Stomach Peptic Ulcer Treatment 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Stomach Peptic Ulcer Treatment 麻豆原创 Size by Region (2020-2025)
6.2 APAC Stomach Peptic Ulcer Treatment 麻豆原创 Size by Type (2020-2025)
6.3 APAC Stomach Peptic Ulcer Treatment 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Stomach Peptic Ulcer Treatment 麻豆原创 Size by Country (2020-2025)
7.2 Europe Stomach Peptic Ulcer Treatment 麻豆原创 Size by Type (2020-2025)
7.3 Europe Stomach Peptic Ulcer Treatment 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Stomach Peptic Ulcer Treatment by Region (2020-2025)
8.2 Middle East & Africa Stomach Peptic Ulcer Treatment 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Stomach Peptic Ulcer Treatment 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Stomach Peptic Ulcer Treatment 麻豆原创 Forecast
10.1 Global Stomach Peptic Ulcer Treatment Forecast by Region (2026-2031)
10.1.1 Global Stomach Peptic Ulcer Treatment Forecast by Region (2026-2031)
10.1.2 Americas Stomach Peptic Ulcer Treatment Forecast
10.1.3 APAC Stomach Peptic Ulcer Treatment Forecast
10.1.4 Europe Stomach Peptic Ulcer Treatment Forecast
10.1.5 Middle East & Africa Stomach Peptic Ulcer Treatment Forecast
10.2 Americas Stomach Peptic Ulcer Treatment Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.2.2 Canada 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.2.3 Mexico 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.2.4 Brazil 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.3 APAC Stomach Peptic Ulcer Treatment Forecast by Region (2026-2031)
10.3.1 China Stomach Peptic Ulcer Treatment 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.3.3 Korea 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.3.4 Southeast Asia 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.3.5 India 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.3.6 Australia 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.4 Europe Stomach Peptic Ulcer Treatment Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.4.2 France 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.4.3 UK 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.4.4 Italy 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.4.5 Russia 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.5 Middle East & Africa Stomach Peptic Ulcer Treatment Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.5.2 South Africa 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.5.3 Israel 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.5.4 Turkey 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
10.6 Global Stomach Peptic Ulcer Treatment Forecast by Type (2026-2031)
10.7 Global Stomach Peptic Ulcer Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Stomach Peptic Ulcer Treatment Forecast
11 Key Players Analysis
11.1 Daewoong Pharmaceutical Co., Ltd.
11.1.1 Daewoong Pharmaceutical Co., Ltd. Company Information
11.1.2 Daewoong Pharmaceutical Co., Ltd. Stomach Peptic Ulcer Treatment Product Offered
11.1.3 Daewoong Pharmaceutical Co., Ltd. Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Daewoong Pharmaceutical Co., Ltd. Main Business Overview
11.1.5 Daewoong Pharmaceutical Co., Ltd. Latest Developments
11.2 Takeda Pharmaceutical Company Limited
11.2.1 Takeda Pharmaceutical Company Limited Company Information
11.2.2 Takeda Pharmaceutical Company Limited Stomach Peptic Ulcer Treatment Product Offered
11.2.3 Takeda Pharmaceutical Company Limited Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.2.5 Takeda Pharmaceutical Company Limited Latest Developments
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Information
11.3.2 Pfizer Inc. Stomach Peptic Ulcer Treatment Product Offered
11.3.3 Pfizer Inc. Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Pfizer Inc. Main Business Overview
11.3.5 Pfizer Inc. Latest Developments
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Information
11.4.2 Abbott Laboratories Stomach Peptic Ulcer Treatment Product Offered
11.4.3 Abbott Laboratories Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Abbott Laboratories Main Business Overview
11.4.5 Abbott Laboratories Latest Developments
11.5 AstraZeneca plc.
11.5.1 AstraZeneca plc. Company Information
11.5.2 AstraZeneca plc. Stomach Peptic Ulcer Treatment Product Offered
11.5.3 AstraZeneca plc. Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 AstraZeneca plc. Main Business Overview
11.5.5 AstraZeneca plc. Latest Developments
11.6 Cadila Healthcare Ltd.
11.6.1 Cadila Healthcare Ltd. Company Information
11.6.2 Cadila Healthcare Ltd. Stomach Peptic Ulcer Treatment Product Offered
11.6.3 Cadila Healthcare Ltd. Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Cadila Healthcare Ltd. Main Business Overview
11.6.5 Cadila Healthcare Ltd. Latest Developments
11.7 Boehringer Ingelheim GmbH
11.7.1 Boehringer Ingelheim GmbH Company Information
11.7.2 Boehringer Ingelheim GmbH Stomach Peptic Ulcer Treatment Product Offered
11.7.3 Boehringer Ingelheim GmbH Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Boehringer Ingelheim GmbH Main Business Overview
11.7.5 Boehringer Ingelheim GmbH Latest Developments
11.8 Eisai Co. Ltd.
11.8.1 Eisai Co. Ltd. Company Information
11.8.2 Eisai Co. Ltd. Stomach Peptic Ulcer Treatment Product Offered
11.8.3 Eisai Co. Ltd. Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Eisai Co. Ltd. Main Business Overview
11.8.5 Eisai Co. Ltd. Latest Developments
11.9 Yuhan Corporation
11.9.1 Yuhan Corporation Company Information
11.9.2 Yuhan Corporation Stomach Peptic Ulcer Treatment Product Offered
11.9.3 Yuhan Corporation Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Yuhan Corporation Main Business Overview
11.9.5 Yuhan Corporation Latest Developments
11.10 GlaxoSmithKline plc.
11.10.1 GlaxoSmithKline plc. Company Information
11.10.2 GlaxoSmithKline plc. Stomach Peptic Ulcer Treatment Product Offered
11.10.3 GlaxoSmithKline plc. Stomach Peptic Ulcer Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 GlaxoSmithKline plc. Main Business Overview
11.10.5 GlaxoSmithKline plc. Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.